1. Home
  2. HBT vs DRTS Comparison

HBT vs DRTS Comparison

Compare HBT & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HBT Financial Inc.

HBT

HBT Financial Inc.

HOLD

Current Price

$35.42

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$15.14

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBT
DRTS
Founded
1920
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
HBT
DRTS
Price
$35.42
$15.14
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$30.75
$8.67
AVG Volume (30 Days)
79.0K
579.5K
Earning Date
04-27-2026
05-18-2026
Dividend Yield
3.29%
N/A
EPS Growth
7.96
N/A
EPS
1.12
N/A
Revenue
N/A
N/A
Revenue This Year
$35.73
N/A
Revenue Next Year
$7.01
$699.98
P/E Ratio
$31.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.36
$3.43
52 Week High
$37.51
$15.79

Technical Indicators

Market Signals
Indicator
HBT
DRTS
Relative Strength Index (RSI) 47.83 59.67
Support Level $35.14 $13.73
Resistance Level $37.08 N/A
Average True Range (ATR) 0.65 0.66
MACD -0.13 0.02
Stochastic Oscillator 24.16 73.06

Price Performance

Historical Comparison
HBT
DRTS

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: